Celldex Therapeutics (CLDX) +6.1% premarket after announcing positive three-year survival data...

|About: Celldex Therapeutics, Inc (CLDX)|By:, SA News Editor

Celldex Therapeutics (CLDX) +6.1% premarket after announcing positive three-year survival data for its rindopepimut Phase 2 clinical program. Data suggests "a substantial and continuing survival benefit in comparison to independent control datasets," and strongly supports an ongoing Phase 3 clinical program, CLDX says.